Quantcast

Latest Symphogen Stories

2014-12-09 23:03:35

Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment

2014-10-14 08:33:06

-- CIAO!(TM) Technology Maximizes Selectivity of Conditionally Active Antibodies -- SAN DIEGO, Oct.

2014-02-25 23:36:32

Gallus BioPharmaceuticals, LLC, a premier pure-play biologics contract manufacturing organization has signed a manufacturing agreement with Symphogen, A/S, a private biopharmaceutical company

2014-01-14 16:25:04

COPENHAGEN, Denmark, January 14, 2014 /PRNewswire/ -- Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic

2014-01-14 12:26:37

PASADENA, Calif., Jan.

2008-07-17 12:01:18

Symphogen and Biovitrum have announced the recruitment of the first patient into a Phase II clinical trial, initiated in June 2008 to evaluate the safety and efficacy, and explore the dose range of Sym001 in idiopathic thrombocytopenic purpura patients.

2008-07-16 09:01:20

COPENHAGEN, Denmark and STOCKHOLM, Sweden- July 16, 2008.


Word of the Day
definiens
  • The word or words serving to define another word or expression, as in a dictionary entry.
The word 'definiens' comes from the Latin word 'definire', 'to define'.
Related